https://www.onhealthcare.tech/p/when-the-toolmaker-decides-to-alsoThoughts on Healthcare Markets & Technologyen2026-07-06T12:32:57+00:00When the Toolmaker Decides to Also Make the Drugs: Anthropic’s Claude Science Launch, Its In-House Preclinical Bet on Neglected Diseases & What Tool Vs. Competitor Tension Means for Pharma AIhttps://www.onhealthcare.tech/p/part-ii-when-the-toolmaker-decidesThoughts on Healthcare Markets & Technologyen2026-07-06T12:20:54+00:00Part II: When the Toolmaker Decides to Also Make the Drugs: Anthropic’s Claude Science Launch, Its In-House Preclinical Bet on Neglected Diseases & What Tool Vs. Competitor Tension Means for Pharma AIhttps://www.onhealthcare.tech/p/part-i-when-the-toolmaker-decidesThoughts on Healthcare Markets & Technologyen2026-07-06T12:18:06+00:00Part I: When the Toolmaker Decides to Also Make the Drugs: Anthropic’s Claude Science Launch, Its In-House Preclinical Bet on Neglected Diseases & What Tool Vs. Competitor Tension Means for Pharma AIhttps://www.onhealthcare.tech/p/the-site-of-care-migration-engine-593Thoughts on Healthcare Markets & Technologyen2026-07-05T15:02:12+00:00The Site-of-Care Migration Engine: The Company to Build on the CY2027 OPPS and ASC Rule’s IPO Phase-Out, Site-Neutral Imaging, 340B ASP-Minus-33.4-Percent Haircut, and Price Transparency RFIhttps://www.onhealthcare.tech/p/the-site-of-care-migration-engineThoughts on Healthcare Markets & Technologyen2026-07-05T14:40:42+00:00The Site-of-Care Migration Engine: The Company to Build on the CY2027 OPPS and ASC Rule’s IPO Phase-Out, Site-Neutral Imaging, 340B ASP-Minus-33.4-Percent Haircut, and Price Transparency RFI